Agilent, Invitrogen End Lengthy Patent Battle

Law360, New York (February 6, 2008, 12:00 AM EST) -- Measurement company Agilent Technologies has settled with Invitrogen Corp. in three long-running patent infringement suits over genetic technology between Invitrogen and Stratagene Corp., which Agilent took over last year.

Santa Clara, Calif.-based Agilent will pay an undisclosed sum to Invitrogen and all litigation will be dismissed, according to a joint statement the companies issued Tuesday.

In addition, Agilent has agreed to stop selling its RNase H minus reverse transcriptase products, and Invitrogen will get a license from Agilent and pay a confidential royalty fee to sell...
To view the full article, register now.